AVITA Medical (NASDAQ:RCEL – Get Free Report) will be releasing its earnings data after the market closes on Thursday, November 7th. Analysts expect AVITA Medical to post earnings of ($0.41) per share for the quarter. Persons that wish to register for the company’s earnings conference call can do so using this link.
AVITA Medical (NASDAQ:RCEL – Get Free Report) last posted its quarterly earnings data on Thursday, August 8th. The company reported ($0.60) earnings per share for the quarter, missing the consensus estimate of ($0.59) by ($0.01). AVITA Medical had a negative net margin of 92.04% and a negative return on equity of 118.27%. The business had revenue of $15.20 million during the quarter, compared to the consensus estimate of $15.04 million. During the same period in the prior year, the company posted ($0.41) earnings per share. On average, analysts expect AVITA Medical to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
AVITA Medical Stock Up 8.4 %
RCEL opened at $11.17 on Tuesday. The stock has a market capitalization of $290.31 million, a price-to-earnings ratio of -5.73 and a beta of 1.54. AVITA Medical has a 1-year low of $7.51 and a 1-year high of $18.93. The business has a 50 day moving average of $10.10 and a 200-day moving average of $9.25. The company has a current ratio of 5.29, a quick ratio of 4.81 and a debt-to-equity ratio of 1.71.
Analyst Ratings Changes
Read Our Latest Research Report on RCEL
About AVITA Medical
AVITA Medical, Inc, together with its subsidiaries, operates as a regenerative medicine company in the United States and internationally. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds, full-thickness skin defects, and repigmentation of stable depigmented vitiligo lesions.
Featured Articles
- Five stocks we like better than AVITA Medical
- What Are Dividend Champions? How to Invest in the Champions
- Intel: Is Now the Time to Be Brave?
- How Can Investors Benefit From After-Hours Trading
- Carnival or Royal Caribbean—Which Cruise Stock Has More Upside?
- 3 Stocks to Consider Buying in October
- Summit Therapeutics: Is Their Lung Cancer Drug a Game Changer?
Receive News & Ratings for AVITA Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AVITA Medical and related companies with MarketBeat.com's FREE daily email newsletter.